Company Registration No. 02624214 (England and Wales)
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
COMPANY INFORMATION
Directors
CL Macau Jr
V Mendelson
(Appointed 5 February 2025)
D McGivern
(Appointed 5 February 2025)
Secretary
Mrs L Coppard
Company number
02624214
Registered office
HVT Centre
Rontgen Place
Great Notley
Braintree
Essex
CM77 7AX
Auditor
Rickard Luckin Limited
1st Floor
County House
100 New London Road
Chelmsford
Essex
CM2 0RG
Bankers
JP Morgan Chase and Co
19th Floor
25 Bank Street
London
E14 5JP
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
CONTENTS
Page
Strategic report
1 - 2
Directors' report
3
Directors' responsibilities statement
4
Independent auditor's report
5 - 8
Statement of comprehensive income
9
Balance sheet
10
Statement of changes in equity
11
Statement of cash flows
12
Notes to the financial statements
13 - 23
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 OCTOBER 2025
- 1 -

The directors present the strategic report for the year ended 31 October 2025.

Principal activities

The Company's principal activities during the year were the development, manufacture of and testing of high voltage interconnection systems. High voltage interconnection systems are found across a broad cross section of industrial, medical, commercial & scientific applications.

Review of the business

The Company's key financial performance indicators during the year were as follows:

 

                    2025     2024    

                    £'000     £'000

Revenue             6,799 7,147

Operating Profit                2,815     2,190    

Earnings Before Interest & Taxes (EBIT)    2,815     2,190    

EBITDA                    2,979     2,222         

 

Average number of employees         51     50

 

This statement reflects a resilient performance in the face of significant and dynamic global events. Stability in our revenue has been achieved by remaining adaptable and agile in our operational decisions considering external pressures.

 

New ‘HVT Centre’ facility, Horizon 120 Braintree CM77 7AX – Relocation from Dunmow completed July 2025.

Customers have expressed confidence in our strategic direction and highlighted the strength of our operational improvements and capacity. Our focus on collaboration for new projects is well received and showcases our dedication to delivering innovative solutions and strengthening partnerships.

Principal risks and uncertainties
The Company maintains a co-ordinated set of risk management and control systems, including strategic planning and management reporting, to help anticipate, measure, monitor and manage its exposure to risk. Risks which the Company faces include:
RISK & POTENTIAL EFFECT
MITIGATING ACTIONS
Global markets
Essex X-Ray's is subject to UK and global political and macro-economic conditions. A number of the Company's products are supplied for use into industries which are dependent upon, and subject to, government policies and national and international political considerations and budgetary constraints. Reduction in military spending or prolonged downturn due to recession or economic instability would adversely affect our sales.
• Increasing diversity of products through ongoing development of strategic growth application areas.
• Expanding geographical spread.
• Maintaining flexibility within the cost base to enable prompt response to significant changes in market conditions and demand.
• Strengthening sales management processes.
Advancement in technology
Essex X-Ray operates in competitive global markets characterised by continuous technological development which is integral to the Company's business of design and manufacture of specialist technology for high performance systems and equipment. Failure to innovate could result in our product offering becoming obsolete. The development of new technologies carries risks including failure to develop a commercially viable offering, taking longer to reach the market than planned and the risk that market size will be smaller than originally envisaged.
• Focusing research and development programmes on innovations consistent with the Company's strategic aims.
• Working closely with customers and to ensure the Company develops solutions tailored to their needs and involving them extensively during product development.
• Working closely with other companies in the Group to share technologies.
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 2 -

Exposure to credit, liquidity, cash flow and price risk

The Company’s operations expose it to a variety of financial risks that include the effects of credit risk, currency risk and liquidity risk:

 

Credit risk

Essex X-Ray does not borrow from any third parties other than its ultimate parent company HEICO Corporation, registered in the USA. Essex X-Ray is wholly owned by HEICO Corporation; the associated financial risk is therefore considered negligible.

Essex X-Ray does not offer credit to any new customers and closely monitors all debtor balances to ensure that customer's accounts do not escalate; accounts are put on stop should they go beyond reasonable lateness and credit facilities are withdrawn for any customer who repeatedly lets their credit account go overdue. Essex X-Ray does not offer credit for any one-off orders.

 

Currency risk

Essex X-ray operates in both USD and EUR, which helps reduce currency exchange risk through natural hedging. However, surplus EUR funds accumulate because the Company sells more in EUR than it buys, creating potential exposure when converting EUR to GBP. Essex X-Ray records monthly exchange gains or losses on all bank, debtor, and creditor balances in the Income Statement. Historically, these fluctuations have resulted in both gains and losses, mitigating significant risk over time.

 

Liquidity risk

The primary liquidity risk for Essex X-Ray relates to the significant investment in a purpose-built facility completed over the past two years. While the build quality and fit-out standards ensured that the cost did not exceed the building’s value, this investment required careful financial planning. Depreciation has been calculated conservatively by management to mitigate risk.

Being wholly owned by HEICO Corporation significantly reduces liquidity risk, as Essex X-Ray adheres strictly to HEICO’s policies and procedures and provides full monthly financial exposure to HEICO. The company actively manages its cash and borrowing requirements to maximize interest income, minimize interest expense, and maintain sufficient liquid resources to meet operational needs.

On behalf of the board

..............................
D McGivern
Director
Date: .............................................
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 OCTOBER 2025
- 3 -

The directors present their annual report and financial statements for the year ended 31 October 2025.

Results and dividends

The results for the year are set out on page 9.

Ordinary dividends were paid amounting to £974,680. The directors do not recommend payment of a final dividend.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

CL Macau Jr
V Mendelson
(Appointed 5 February 2025)
D McGivern
(Appointed 5 February 2025)
Strategic report

The company has chosen in accordance with Companies Act 2006, s. 414C(11) to set out in the company's strategic report information required by Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008, Sch. 7 to be contained in the directors' report. It has done so in respect of financial risk disclosures, future developments and subsequent events.

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.

Auditor

In accordance with the company's articles, a resolution proposing that Rickard Luckin Limited be reappointed as auditor of the company will be put at a General Meeting.

Medium-sized companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the medium-sized companies exemption.

On behalf of the board
D McGivern
Director
20 August 2026
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 OCTOBER 2025
- 4 -

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the director is required to:

 

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
- 5 -
Opinion

We have audited the financial statements of Essex X-Ray and Medical Equipment Limited (the 'company') for the year ended 31 October 2025 which comprise the statement of comprehensive income, the balance sheet, the statement of changes in equity, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
- 6 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report and the Directors' Report.

 

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

 

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Capability of the audit in detecting irregularity, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

We identified areas of laws and regulations that could reasonably be expected to have a material effect on the financial statements from our: general commercial and sector experience; through verbal and written communications with those charged with governance and other management; and via inspection of the company’s regulatory and legal correspondence.

We discussed with those charged with governance and other management the policies and procedures regarding compliance with laws and regulations.

We communicated identified laws and regulations to our team and remained alert to any indicators of non-compliance throughout the audit, we also specifically considered where and how fraud may occur within the company.

The potential effect of these laws and regulations on the financial statements varies considerably.

Firstly, the company is subject to laws and regulations that directly affect the financial statements, including: the company’s constitution, relevant financial reporting standards; company law; tax legislation and distributable profits legislation and we assess the extent of compliance with these laws and regulations as part of our procedures on the related financial statement items.

ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
- 7 -

Secondly the company is subject to many other laws and regulations where the consequences of non-compliance could have a material effect on the amounts or disclosures in the financial statements, for instance through the imposition of fines and penalties, or through losses arising from litigations. We identified the following areas as those most likely to have such an affect: employment legislation; health and safety legislation; data protection legislation; OFAC trading compliance; anti-bribery and anti-corruption legislation.

ISAs (UK) limit the required procedures to identify non-compliance with these laws and regulations, and no procedures over and above those already noted are required. These limited procedures did not identify any actual or suspected non-compliance with laws and regulations that could have a material impact on the financial statements.

In relation to fraud, we performed the following specific procedures in addition to those already noted:

These procedures did not identify any actual or suspected fraudulent irregularity that could have a material impact on the financial statements.

Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with ISAs (UK). For example, the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely the procedures that we are required to undertake would identify it. In addition, as with any audit, there remains a high risk of non-detection of irregularities, as these might involve collusion, forgery, intentional omissions, misrepresentation, or the override of internal controls. We are not responsible for preventing non-compliance with laws and regulations or fraud, and cannot be expected to detect non-compliance with all laws and regulations or every incidence of fraud.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
- 8 -

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Joanna Southon (Senior Statutory Auditor)
For and on behalf of Rickard Luckin Limited
20 August 2026
Chartered Accountants
Statutory Auditor
1st Floor
County House
100 New London Road
Chelmsford
Essex
CM2 0RG
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 OCTOBER 2025
- 9 -
2025
2024
Notes
£
£
Turnover
3
6,799,702
7,146,682
Cost of sales
(4,115,290)
(4,104,747)
Gross profit
2,684,412
3,041,935
Administrative expenses
(952,542)
(851,696)
Profit/(loss) on disposal of property
4
1,083,348
-
0
Operating profit
5
2,815,218
2,190,239
Interest receivable and similar income
8
3,632
-
0
Interest payable and similar expenses
9
(608,219)
(283,970)
Profit before taxation
2,210,631
1,906,269
Tax on profit
10
-
0
-
0
Profit and total comprehensive income for the financial year
21
2,210,631
1,906,269

The profit and loss account has been prepared on the basis that all operations are continuing operations.

ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
BALANCE SHEET
AS AT 31 OCTOBER 2025
31 October 2025
- 10 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
12
14,072,323
11,337,893
Current assets
Stocks
13
1,661,324
1,076,433
Debtors
14
1,461,362
2,102,196
Cash at bank and in hand
1,695,717
365,627
4,818,403
3,544,256
Creditors: amounts falling due within one year
15
(12,156,762)
(9,167,992)
Net current liabilities
(7,338,359)
(5,623,736)
Total assets less current liabilities
6,733,964
5,714,157
Creditors: amounts falling due after more than one year
16
(884,760)
(1,100,904)
Net assets
5,849,204
4,613,253
Capital and reserves
Called up share capital
19
100
100
Profit and loss reserves
21
5,849,104
4,613,153
Total equity
5,849,204
4,613,253

These financial statements have been prepared in accordance with the provisions relating to medium-sized companies.

The financial statements were approved by the board of directors and authorised for issue on 20 August 2026 and are signed on its behalf by:
D McGivern
Director
Company registration number 02624214 (England and Wales)
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 OCTOBER 2025
- 11 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 November 2023
100
3,476,731
3,476,831
Year ended 31 October 2024:
Profit and total comprehensive income
-
1,906,269
1,906,269
Dividends
11
-
(769,847)
(769,847)
Balance at 31 October 2024
100
4,613,153
4,613,253
Year ended 31 October 2025:
Profit and total comprehensive income
-
2,210,631
2,210,631
Dividends
11
-
(974,680)
(974,680)
Balance at 31 October 2025
100
5,849,104
5,849,204
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 OCTOBER 2025
- 12 -
2025
2024
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from operations
25
2,693,670
704,635
Interest paid
-
(10,608)
Income taxes paid
(156,983)
(494,075)
Net cash inflow from operating activities
2,536,687
199,952
Investing activities
Purchase of tangible fixed assets
(2,993,376)
(6,445,872)
Proceeds from disposal of tangible fixed assets
3,026
4,220
Proceeds from disposal of freehold property
1,174,779
-
0
Interest received
3,632
-
0
Net cash used in investing activities
(1,811,939)
(6,441,652)
Financing activities
Proceeds from borrowings
2,060,689
6,671,844
Repayment of borrowings
(480,667)
-
0
Dividends paid
(974,680)
(769,847)
Net cash generated from financing activities
605,342
5,901,997
Net increase/(decrease) in cash and cash equivalents
1,330,090
(339,703)
Cash and cash equivalents at beginning of year
365,627
705,330
Cash and cash equivalents at end of year
1,695,717
365,627
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025
- 13 -
1
Accounting policies
Company information

Essex X-Ray and Medical Equipment Limited is a private company limited by shares incorporated in England and Wales. The registered office is HVT Centre, Rontgen Place, Great Notley, Braintree, Essex, CM77 7AX.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for at least the next 12 months from when the financial statements are authorised for issue. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.4
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that technical, commercial and financial feasibility can be demonstrated.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold property
Nil on land and 50 years depreciation to a residual balance of 65% on buildings cost
Plant and machinery
20% on net book value
Fixtures, fittings & equipment
20% on net book value and 33.33% on computer cost
Motor vehicles
25% on net book value

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
- 14 -

No depreciation is charged against assets under construction until they are brought into use. At this point the asset will be transferred into a fixed assets category.

1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

1.7
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.8
Cash at bank and in hand

Cash at bank and in hand are basic financial assets and include cash in hand and deposits held at call with banks.

1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
- 15 -
Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors and loans from fellow group companies, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
- 16 -
1.11
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.13
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.14
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

1.15

Exceptional items

Exceptional items are items of income or expense that, in the judgement of management, should be disclosed separately on the basis that they are material, either by their nature or their size, to an understanding of our financial performance and significantly distort the comparability of financial performance between periods.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.

Depreciation

The depreciation expense is the recognition of the decline in the value of the asset and allocation of the cost of the asset over the periods in which the asset will be used. Judgements are made on the estimated useful life of the assets which are regularly reviewed to reflect the changing environment.

Stocks

Judgement is made on the write down of parts for obsolescence based on the age and last movement dates of items.

ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 17 -
3
Turnover and other income
2025
2024
£
£
Turnover analysed by class of business
Manufacture and sale of goods
6,799,702
7,146,682
2025
2024
£
£
Turnover analysed by geographical market
United Kingdom
3,733,381
3,474,518
Rest of the World
710,710
925,123
Europe
2,355,611
2,747,041
6,799,702
7,146,682
2025
2024
£
£
Other income
Interest income
3,632
-
4
Exceptional item
2025
2024
£
£
(Profit)/loss on disposal of tangible fixed assets
(1,083,348)
-

The exceptional item relates to profit on disposal of freehold property.

5
Operating profit
2025
2024
Operating profit for the year is stated after charging/(crediting):
£
£
Exchange losses
52,541
67,953
Research and development costs
2,371
2,281
Fees payable to the company's auditor for the audit of the company's financial statements
33,550
19,900
Depreciation of tangible fixed assets
164,090
31,700
Loss/(profit) on disposal of tangible fixed assets
399
(2,184)
Exceptional item
(1,083,438)
-
0
Operating lease charges
25,055
27,825
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 18 -
6
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Production
34
33
Directors
1
1
Administration
16
16
Total
51
50

Their aggregate remuneration comprised:

2025
2024
£
£
Wages and salaries
1,932,772
1,811,581
Social security costs
241,823
196,657
Pension costs
2,885
-
0
2,177,480
2,008,238
7
Directors' remuneration
2025
2024
£
£
Remuneration for qualifying services
96,179
-
0
Company pension contributions to defined contribution schemes
2,885
-
99,064
-
0

The number of directors for whom retirement benefits are accruing under defined contribution schemes amounted to 1 (2024 - 0).

8
Interest receivable and similar income
2025
2024
£
£
Interest income
Other interest income
3,632
-
0
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 19 -
9
Interest payable and similar expenses
2025
2024
£
£
Interest on financial liabilities measured at amortised cost:
Interest payable to group undertakings
608,219
273,361
Other finance costs:
Other interest
-
0
10,609
608,219
283,970
10
Taxation

The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:

2025
2024
£
£
Profit before taxation
2,210,631
1,906,269
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2024: 25.00%)
552,658
476,567
Tax effect of expenses that are not deductible in determining taxable profit
(21,356)
71,040
Gains not taxable
(234,623)
-
0
Change in unrecognised deferred tax assets
(296,679)
123,982
Capital allowances in excess of depreciation
-
0
(672,387)
Depreciation on assets not qualifying for tax allowances
-
0
798
Taxation charge for the year
-
-
11
Dividends
2025
2024
£
£
Total dividends
Interim paid
974,680
769,847
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 20 -
12
Tangible fixed assets
Freehold property
Assets under construction
Plant and machinery
Fixtures, fittings & equipment
Motor vehicles
Total
£
£
£
£
£
£
Cost
At 1 November 2024
2,593,751
9,117,426
424,276
171,942
12,439
12,319,834
Additions
-
0
2,341,337
339,589
312,450
-
0
2,993,376
Disposals
(564,340)
-
0
(33,342)
(22,099)
-
0
(619,781)
Transfers
11,458,763
(11,458,763)
-
0
-
0
-
0
-
0
At 31 October 2025
13,488,174
-
0
730,523
462,293
12,439
14,693,429
Depreciation and impairment
At 1 November 2024
472,907
-
0
336,635
160,665
11,734
981,941
Depreciation charged in the year
26,740
-
0
85,198
51,977
175
164,090
Eliminated in respect of disposals
(472,910)
-
0
(32,100)
(19,915)
-
0
(524,925)
At 31 October 2025
26,737
-
0
389,733
192,727
11,909
621,106
Carrying amount
At 31 October 2025
13,461,437
-
0
340,790
269,566
530
14,072,323
At 31 October 2024
2,120,844
9,117,426
87,641
11,277
705
11,337,893
13
Stocks
2025
2024
£
£
Raw materials and consumables
1,571,217
1,032,961
Work in progress
20,501
10,165
Finished goods and goods for resale
69,606
33,307
1,661,324
1,076,433
14
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
899,227
851,363
Corporation tax recoverable
512,846
355,863
Amounts owed by group undertakings
12,449
481,494
Other debtors
-
0
373,301
Prepayments and accrued income
36,840
40,175
1,461,362
2,102,196
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 21 -
15
Creditors: amounts falling due within one year
2025
2024
Notes
£
£
Loans and overdrafts
17
11,171,000
8,766,615
Trade creditors
478,114
22,647
Amounts owed to group undertakings
4,514
10,867
Taxation and social security
164,192
33,970
Accruals and deferred income
338,942
333,893
12,156,762
9,167,992
16
Creditors: amounts falling due after more than one year
2025
2024
Notes
£
£
Loans and overdrafts
17
884,760
1,100,904
Amounts included above which fall due after five years are as follows:
Payable by instalments
-
219,766
17
Loans and overdrafts
2025
2024
£
£
Loans from group undertakings
12,055,760
9,867,519
Payable within one year
11,171,000
8,766,615
Payable after one year
884,760
1,100,904

Included within amounts payable within one year is a balance of £10,958,906, which relates to the amount drawn down on a loan facility to fund the purchase of the company’s new factory. Once this loan is fully drawn down, its repayment terms will be formalised and a proportion of the debt would then be categorised as being due after one year.

 

The remaining balance of £1,096,854 is a separate loan which is repayable by 2030 in equal annual instalments.

18
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
2,885
-

The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.

ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 22 -
19
Share capital
2025
2024
£
£
Ordinary share capital
Issued and fully paid
100 ordinary shares of £1 each
100
100
20
Financial commitments, guarantees and contingent liabilities

The company's bankers have provided a financial guarantee of £80,000 to HM Revenue and Customs. The company has not provided any specific security with respect to this guarantee.

21
Profit and loss reserves

All profit and loss reserves are distributable.

22
Ultimate controlling party

The immediate parent company is HVT Group Inc. and the ultimate parent undertaking is HEICO Corporation, both of which are registered in the USA. The only company in which the results of Essex X-Ray and Medical Equipment Limited are consolidated is HEICO Corporation. Copies of the consolidated financial statements of HEICO Corporation can be obtained from the company secretary at 3000 Taft Street, Hollywood, FL 33021.

23
Operating lease commitments

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

2025
2024
£
£
Within one year
26,804
19,992
Between two and five years
23,972
18,930
50,776
38,922
24
Related party transactions

At the balance sheet date the company owed £4,514 (2024: £10,867) to a fellow subsidiary. At this date the company was also owed £8,266 (2024: £476,451) by this fellow subsidiary and was owed £4,183 (2024: £7,056) by the ultimate parent company.

 

In addition, during 2021 the company was loaned £2,100,000 by the ultimate parent company for the purchase of land. This loan is repayable over 10 years and interest is charged at a commercial rate. As at 31 October 2025 £1,096,854 (2024: £1,548,095) was the balance outstanding.

 

During 2023 the company was provided a second loan by the ultimate parent company for the construction of the new building. Up to £11,000,000 can be drawn under this loan, and the amount drawn is repayable on demand. Interest is charged at a commercial rate. As at 31 October 2025 £10,958,906 (2024: £8,319,424) was the balance outstanding.

 

The total repayment of borrowing and interests in the year was £480,666 and there was total interest charged of £608,219.

ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 23 -
25
Cash generated from operations
2025
2024
£
£
Profit after taxation
2,210,631
1,906,269
Adjustments for:
Finance costs
608,219
283,970
Investment income
(3,632)
-
0
Loss/(gain) on disposal of tangible fixed assets
399
(2,184)
Gain on disposal of freehold property
(1,083,348)
-
0
Depreciation and impairment of tangible fixed assets
164,090
31,700
Movements in working capital:
(Increase)/decrease in stocks
(584,891)
107,677
Decrease/(increase) in debtors
797,817
(428,178)
Increase/(decrease) in creditors
584,385
(1,194,619)
Cash generated from operations
2,693,670
704,635
26
Analysis of changes in net debt
1 November 2024
Cash flows
Other non-cash changes
31 October 2025
£
£
£
£
Cash at bank and in hand
365,627
1,330,090
-
1,695,717
Borrowings excluding overdrafts
(9,867,519)
(1,580,022)
(608,219)
(12,055,760)
(9,501,892)
(249,932)
(608,219)
(10,360,043)
2025-10-312024-11-01falsefalsefalseCCH SoftwareCCH Accounts Production 2026.100CL Macau JrV MendelsonD McGivernMrs L Coppard026242142024-11-012025-10-3102624214bus:Director12024-11-012025-10-3102624214bus:Director22024-11-012025-10-3102624214bus:Director32024-11-012025-10-3102624214bus:CompanySecretary12024-11-012025-10-3102624214bus:RegisteredOffice2024-11-012025-10-3102624214bus:Agent12024-11-012025-10-31026242142025-10-31026242142023-11-012024-10-310262421412024-11-012025-10-310262421412023-11-012024-10-3102624214core:RetainedEarningsAccumulatedLosses2023-11-012024-10-3102624214core:RetainedEarningsAccumulatedLosses2024-11-012025-10-31026242142024-10-3102624214core:LandBuildingscore:OwnedOrFreeholdAssets2025-10-3102624214core:ConstructionInProgressAssetsUnderConstruction2025-10-3102624214core:PlantMachinery2025-10-3102624214core:FurnitureFittings2025-10-3102624214core:MotorVehicles2025-10-3102624214core:LandBuildingscore:OwnedOrFreeholdAssets2024-10-3102624214core:ConstructionInProgressAssetsUnderConstruction2024-10-3102624214core:PlantMachinery2024-10-3102624214core:FurnitureFittings2024-10-3102624214core:MotorVehicles2024-10-3102624214core:WithinOneYear2025-10-3102624214core:WithinOneYear2024-10-3102624214core:AfterOneYear2025-10-3102624214core:AfterOneYear2024-10-3102624214core:CurrentFinancialInstrumentscore:WithinOneYear2025-10-3102624214core:CurrentFinancialInstrumentscore:WithinOneYear2024-10-3102624214core:ShareCapital2025-10-3102624214core:ShareCapital2024-10-3102624214core:RetainedEarningsAccumulatedLosses2025-10-3102624214core:RetainedEarningsAccumulatedLosses2024-10-3102624214core:ShareCapital2023-10-3102624214core:RetainedEarningsAccumulatedLosses2023-10-3102624214core:ShareCapitalOrdinaryShareClass12025-10-3102624214core:ShareCapitalOrdinaryShareClass12024-10-31026242142024-10-31026242142023-10-3102624214core:LandBuildingscore:OwnedOrFreeholdAssets2024-11-012025-10-3102624214core:PlantMachinery2024-11-012025-10-3102624214core:FurnitureFittings2024-11-012025-10-3102624214core:MotorVehicles2024-11-012025-10-3102624214core:UKTax2024-11-012025-10-3102624214core:UKTax2023-11-012024-10-310262421422024-11-012025-10-310262421422023-11-012024-10-3102624214core:LandBuildingscore:OwnedOrFreeholdAssets2024-10-3102624214core:ConstructionInProgressAssetsUnderConstruction2024-10-3102624214core:PlantMachinery2024-10-3102624214core:FurnitureFittings2024-10-3102624214core:MotorVehicles2024-10-3102624214core:ConstructionInProgressAssetsUnderConstruction2024-11-012025-10-3102624214core:CurrentFinancialInstruments2025-10-3102624214core:CurrentFinancialInstruments2024-10-3102624214core:Non-currentFinancialInstruments2025-10-3102624214core:Non-currentFinancialInstruments2024-10-3102624214core:Non-currentFinancialInstrumentscore:AfterOneYear2025-10-3102624214core:Non-currentFinancialInstrumentscore:AfterOneYear2024-10-3102624214bus:OrdinaryShareClass12024-11-012025-10-3102624214bus:OrdinaryShareClass12025-10-3102624214core:BetweenTwoFiveYears2025-10-3102624214core:BetweenTwoFiveYears2024-10-3102624214bus:PrivateLimitedCompanyLtd2024-11-012025-10-3102624214bus:FRS1022024-11-012025-10-3102624214bus:Audited2024-11-012025-10-3102624214bus:FullAccounts2024-11-012025-10-31xbrli:purexbrli:sharesiso4217:GBP